Suppr超能文献

黏多糖贮积症 I 犬颈椎骨病的产后进展。

Postnatal progression of bone disease in the cervical spines of mucopolysaccharidosis I dogs.

机构信息

Department of Orthopaedic Surgery, Perelman School of Medicine, University of Pennsylvania, 424 Stemmler Hall, 3450 Hamilton Walk, Philadelphia, PA 19104, USA.

出版信息

Bone. 2013 Jul;55(1):78-83. doi: 10.1016/j.bone.2013.03.014. Epub 2013 Apr 4.

Abstract

INTRODUCTION

Mucopolysaccharidosis I (MPS I) is a lysosomal storage disorder characterized by deficient α-l-iduronidase activity leading to accumulation of poorly degraded dermatan and heparan sulfate glycosaminoglycans (GAGs). MPS I is associated with significant cervical spine disease, including vertebral dysplasia, odontoid hypoplasia, and accelerated disk degeneration, leading to spinal cord compression and kypho-scoliosis. The objective of this study was to establish the nature and rate of progression of cervical vertebral bone disease in MPS I using a canine model.

METHODS

C2 vertebrae were obtained post-mortem from normal and MPS I dogs at 3, 6 and 12 months-of-age. Morphometric parameters and mineral density for the vertebral trabecular bone and odontoid process were determined using micro-computed tomography. Vertebrae were then processed for paraffin histology, and cartilage area in both the vertebral epiphyses and odontoid process were quantified.

RESULTS

Vertebral bodies of MPS I dogs had lower trabecular bone volume/total volume (BV/TV), trabecular thickness (Tb.Th), trabecular number (Tb.N) and bone mineral density (BMD) than normals at all ages. For MPS I dogs, BV/TV, Tb.Th and BMD plateaued after 6 months-of-age. The odontoid process appeared morphologically abnormal for MPS I dogs at 6 and 12 months-of-age, although BV/TV and BMD were not significantly different from normals. MPS I dogs had significantly more cartilage in the vertebral epiphyses at both 3 and 6 months-of-age. At 12 months-of-age, epiphyseal growth plates in normal dogs were absent, but in MPS I dogs they persisted.

CONCLUSIONS

In this study we report reduced trabecular bone content and mineralization, and delayed cartilage to bone conversion in MPS I dogs from 3 months-of-age, which may increase vertebral fracture risk and contribute to progressive deformity. The abnormalities of the odontoid process we describe likely contribute to increased incidence of atlanto-axial subluxation observed clinically. Therapeutic strategies that enhance bone formation may decrease incidence of spine disease in MPS I patients.

摘要

简介

黏多糖贮积症 I 型(MPS I)是一种溶酶体贮积症,其特征是缺乏α-L-艾杜糖醛酸酶活性,导致未降解的皮肤素和硫酸乙酰肝素糖胺聚糖(GAGs)积累。MPS I 与显著的颈椎疾病有关,包括椎体发育不良、齿状突发育不良和椎间盘加速退化,导致脊髓压迫和脊柱后凸-侧凸。本研究的目的是使用犬模型确定 MPS I 中颈椎骨疾病的性质和进展速度。

方法

从正常和 MPS I 犬的死后 C2 椎体中,分别在 3、6 和 12 月龄时获得组织学标本。使用微计算机断层扫描技术确定椎骨小梁骨和齿状突的形态参数和骨密度。然后对椎体进行石蜡组织学处理,并定量分析椎体骺和齿状突的软骨面积。

结果

与正常组相比,MPS I 犬的椎体骨小梁体积/总体积(BV/TV)、骨小梁厚度(Tb.Th)、骨小梁数量(Tb.N)和骨密度(BMD)在所有年龄段均较低。对于 MPS I 犬,BV/TV、Tb.Th 和 BMD 在 6 月龄后趋于稳定。6 和 12 月龄时,MPS I 犬的齿状突形态异常,但与正常组相比,BV/TV 和 BMD 无显著差异。3 和 6 月龄时,MPS I 犬的椎体骺板中软骨明显增多。12 月龄时,正常犬的骺板已消失,但 MPS I 犬仍存在。

结论

本研究报告了 MPS I 犬从 3 月龄开始出现的小梁骨含量和矿化减少,以及软骨向骨转化延迟,这可能增加椎体骨折的风险,并导致进行性畸形。我们描述的齿状突异常可能导致临床上观察到的寰枢椎半脱位发生率增加。增强骨形成的治疗策略可能会降低 MPS I 患者脊柱疾病的发生率。

相似文献

1
Postnatal progression of bone disease in the cervical spines of mucopolysaccharidosis I dogs.
Bone. 2013 Jul;55(1):78-83. doi: 10.1016/j.bone.2013.03.014. Epub 2013 Apr 4.
3
Effects of lithium administration on vertebral bone disease in mucopolysaccharidosis I dogs.
Bone. 2022 Jan;154:116237. doi: 10.1016/j.bone.2021.116237. Epub 2021 Oct 22.
5
Progression of vertebral bone disease in mucopolysaccharidosis VII dogs from birth to skeletal maturity.
Mol Genet Metab. 2021 Aug;133(4):378-385. doi: 10.1016/j.ymgme.2021.06.005. Epub 2021 Jun 15.
6
Pathogenesis of lumbar spine disease in mucopolysaccharidosis VII.
Mol Genet Metab. 2012 Sep;107(1-2):153-60. doi: 10.1016/j.ymgme.2012.03.014. Epub 2012 Mar 30.
10
Molecular profiling of failed endochondral ossification in mucopolysaccharidosis VII.
Bone. 2019 Nov;128:115042. doi: 10.1016/j.bone.2019.115042. Epub 2019 Aug 20.

引用本文的文献

1
Modeling skeletal dysplasia in Hurler syndrome using patient-derived bone marrow osteoprogenitor cells.
JCI Insight. 2024 Mar 8;9(5):e173449. doi: 10.1172/jci.insight.173449.
2
MPSI Manifestations and Treatment Outcome: Skeletal Focus.
Int J Mol Sci. 2022 Sep 22;23(19):11168. doi: 10.3390/ijms231911168.
3
Bone Biomarkers in Mucopolysaccharidoses.
Int J Mol Sci. 2021 Nov 23;22(23):12651. doi: 10.3390/ijms222312651.
4
Effects of lithium administration on vertebral bone disease in mucopolysaccharidosis I dogs.
Bone. 2022 Jan;154:116237. doi: 10.1016/j.bone.2021.116237. Epub 2021 Oct 22.
5
Progression of vertebral bone disease in mucopolysaccharidosis VII dogs from birth to skeletal maturity.
Mol Genet Metab. 2021 Aug;133(4):378-385. doi: 10.1016/j.ymgme.2021.06.005. Epub 2021 Jun 15.
6
Failures of Endochondral Ossification in the Mucopolysaccharidoses.
Curr Osteoporos Rep. 2020 Dec;18(6):759-773. doi: 10.1007/s11914-020-00626-y. Epub 2020 Oct 16.
9
Molecular profiling of failed endochondral ossification in mucopolysaccharidosis VII.
Bone. 2019 Nov;128:115042. doi: 10.1016/j.bone.2019.115042. Epub 2019 Aug 20.
10
Pathogenesis and treatment of spine disease in the mucopolysaccharidoses.
Mol Genet Metab. 2016 Aug;118(4):232-43. doi: 10.1016/j.ymgme.2016.06.002. Epub 2016 Jun 4.

本文引用的文献

1
Assessment of bone dysplasia by micro-CT and glycosaminoglycan levels in mouse models for mucopolysaccharidosis type I, IIIA, IVA, and VII.
J Inherit Metab Dis. 2013 Mar;36(2):235-46. doi: 10.1007/s10545-012-9522-x. Epub 2012 Sep 13.
2
Pathogenesis of lumbar spine disease in mucopolysaccharidosis VII.
Mol Genet Metab. 2012 Sep;107(1-2):153-60. doi: 10.1016/j.ymgme.2012.03.014. Epub 2012 Mar 30.
3
Effect of neonatal gene therapy on lumbar spine disease in mucopolysaccharidosis VII dogs.
Mol Genet Metab. 2012 Sep;107(1-2):145-52. doi: 10.1016/j.ymgme.2012.03.013. Epub 2012 Mar 29.
6
Bone, joint and tooth development in mucopolysaccharidoses: relevance to therapeutic options.
Biochim Biophys Acta. 2011 Nov;1812(11):1542-56. doi: 10.1016/j.bbadis.2011.07.013. Epub 2011 Jul 30.
8
9
Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses.
Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):222-7. doi: 10.1073/pnas.0912937107. Epub 2009 Dec 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验